litlas
Log inCreate account

Thomas J. Kipps

Active 1979–2025

251
Papers
66,939
Citations
125
h-index
245
i10-index

Citations

Citations per year for Thomas J. Kipps1975: 1 citations1978: 1 citations1979: 4 citations1980: 6 citations1981: 2 citations1982: 1 citations1983: 3 citations1985: 3 citations1986: 6 citations1987: 5 citations1988: 21 citations1989: 21 citations1990: 26 citations1991: 25 citations1992: 40 citations1993: 36 citations1994: 55 citations1995: 33 citations1996: 43 citations1997: 40 citations1998: 66 citations1999: 74 citations2000: 83 citations2001: 79 citations2002: 121 citations2003: 203 citations2004: 195 citations2005: 293 citations2006: 437 citations2007: 571 citations2008: 818 citations2009: 818 citations2010: 792 citations2011: 707 citations2012: 697 citations2013: 680 citations2014: 589 citations2015: 646 citations2016: 604 citations2017: 668 citations2018: 671 citations2019: 2,058 citations2020: 2,379 citations2021: 2,113 citations2022: 1,549 citations2023: 1,041 citations2024: 1,790 citations2025: 702 citations2026: 26 citations1976–1977: no citations, so these years are not shown1984: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,662 citing papers, 29% of this breakdownChina: 2,013 citing papers, 10.3% of this breakdownGermany: 1,231 citing papers, 6.3% of this breakdownItaly: 1,223 citing papers, 6.3% of this breakdownUnited Kingdom: 1,132 citing papers, 5.8% of this breakdownFrance: 679 citing papers, 3.5% of this breakdownAustralia: 632 citing papers, 3.2% of this breakdownSpain: 577 citing papers, 2.9% of this breakdownCanada: 480 citing papers, 2.4% of this breakdownJapan: 461 citing papers, 2.4% of this breakdownNetherlands: 422 citing papers, 2.2% of this breakdownIndia: 391 citing papers, 2% of this breakdown
0%29%Other 23.7%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology45.8%
  • Medicine45.4%
  • Immunology and Microbiology6.2%
  • Computer Science0.5%
  • Engineering0.5%
  • Neuroscience0.3%
  • Other1.3%

Topics

  • MicroRNA in disease regulation8.5%
  • Chronic Lymphocytic Leukemia Research8.4%
  • Cancer-related molecular mechanisms research5.5%
  • Lymphoma Diagnosis and Treatment5%
  • Circular RNAs in diseases4.8%
  • RNA modifications and cancer3.1%
  • Other64.7%

Coauthors

All papers

Open in search
  1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Authors: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 cited by 1,689

  2. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Authors: Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour - New England Journal of Medicine 2015 cited by 1,884

  3. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

    Authors: George A. Calin, Calin Dan Dumitru, Masayoshi Shimizu, Roberta Bichi, Simona Zupo, Evan Noch, Hansjuerg Aldler, Sashi Rattan, Michael J. Keating, Kanti Rai, Laura Z. Rassenti, Thomas J. Kipps, Massimo Negrini, Florencia Bullrich, Carlo M. Croce - National Academy of Sciences, Proceedings of the National Academy of Sciences 2002 cited by 5,018

  4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    Authors: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 cited by 1,562

  5. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Authors: Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna‐Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova, A. M. Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, Rod Humerickhouse, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl-Anton Kreuzer, Matthias Ritgen, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek - New England Journal of Medicine 2019 cited by 852

  6. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Authors: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, John F. Gerecitano, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A. Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P. Kater - New England Journal of Medicine 2018 cited by 909

  7. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    Authors: Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia - Blood Advances 2022 cited by 269

  8. miR-15 and miR-16 induce apoptosis by targeting BCL2

    Authors: Amelia Cimmino, George A. Calin, Muller Fabbri, Marilena V. Iorio, Manuela Ferracin, Masayoshi Shimizu, Sylwia E. Wojcik, Rami I. Aqeilan, Simona Zupo, Mariella Dono, Laura Z. Rassenti, Hansjüerg Alder, Stefano Volinia, Chang‐Gong Liu, Thomas J. Kipps, Massimo Negrini, Carlo M. Croce - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 3,521

  9. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

    Authors: Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia - Blood 2022 cited by 238

  10. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    Authors: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 cited by 1,617

  11. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Authors: Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach - American Journal of Hematology 2019 cited by 473

  12. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    Authors: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer‐Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam - Journal of Clinical Oncology 2021 cited by 229

  13. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    Authors: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 cited by 1,684

  14. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Authors: Andrew W. Roberts, John F. Seymour, Jennifer R. Brown, William G. Wierda, Thomas J. Kipps, Seong Lin Khaw, Dennis Carney, Simon He, David C.S. Huang, Hao Xiong, Yue Cui, Todd Busman, Evelyn McKeegan, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse - Journal of Clinical Oncology 2011 cited by 818

  15. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Authors: Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori A. Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod Humerickhouse, Gary Gordon, John F. Gerecitano - Journal of Clinical Oncology 2017 cited by 751

  16. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Authors: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Kanti R. Rai, Thomas J. Kipps - Blood 2008 cited by 3,193

  17. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

    Authors: Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna‐Maria Fink, Sandra Robrecht, Olga Samoylova, Anna Marina Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens‐Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer - The Lancet Oncology 2020 cited by 327

  18. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

    Authors: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, James D’Rozario, Carolyn Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater - Blood 2022 cited by 151

  19. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Authors: Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps - Leukemia 2019 cited by 463

  20. cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies

    Authors: Christina B. Pedersen, Søren Helweg Dam, Mike Bogetofte Barnkob, Michael D. Leipold, Noelia Purroy, Laura Z. Rassenti, Thomas J. Kipps, Jennifer P. Nguyen, James A. Lederer, Satyen H. Gohil, Catherine J. Wu, Lars Rønn Olsen - Nature Communications 2022 cited by 126

  21. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

    Authors: Arnon P. Kater, Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Julie Dubois, Eric Eldering, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Su Young Kim, Brenda Chyla, Elizabeth A. Punnoose, Christopher R. Bolen, Zoe J. Assaf, Yanwen Jiang, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, John F. Seymour - Journal of Clinical Oncology 2020 cited by 220

  22. Molecular map of chronic lymphocytic leukemia and its impact on outcome

    Authors: Binyamin A. Knisbacher, Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Martí Duran‐Ferrer, Kristen E. Stevenson, Eugen Tausch, Julio Delgado, Alex Barbera-Mourelle, Amaro Taylor‐Weiner, Pablo Bousquets‐Muñoz, Ander Díaz‐Navarro, Andrew Dunford, Shankara Anand, Helene Kretzmer, Jesús Gutiérrez‐Abril, Sara López-Tamargo, Stacey M. Fernandes, Clare Sun, Mariela Sivina, Laura Z. Rassenti, Christof Schneider, Shuqiang Li, Laxmi Parida, Alexander Meissner, François Aguet, Jan A. Burger, Adrian Wiestner, Thomas J. Kipps, Jennifer R. Brown, Michael Hallek, Chip Stewart, Donna Neuberg, José I. Martín‐Subero, Xosé S. Puente, Stephan Stilgenbauer, Catherine J. Wu, Elı́as Campo, Gad Getz - Nature Genetics 2022 cited by 148

  23. ROR1: an orphan becomes apparent

    Authors: Thomas J. Kipps - Blood 2022 cited by 82

  24. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

    Authors: Michael Y. Choi, George F. Widhopf, Emanuela M. Ghia, Reilly L. Kidwell, Md Kamrul Hasan, Jian Yu, Laura Z. Rassenti, Liguang Chen, Yun Chen, Emily Pittman, Minya Pu, Karen Messer, Charles Prussak, Januario E. Castro, Catriona Jamieson, Thomas J. Kipps - Cell stem cell 2018 cited by 187